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Abstract
Background: It is known that cetuximab (an epidermal growth factor receptor [EGFr] inhibitor) is a radiosensitizer.
Also, cetuximab is known to only partially inhibit the signal transducer and activator of transcription – 3 (STAT-3);
a mediator of protection from apoptosis. Studies were performed to determine if the radiosensitizing effects of
cetuximab could be enhanced with the addition of an inhibitor of STAT-3.
Methods/Results: The interaction of JAK-STAT-3 inhibition ([JAK1i]; Calbiochem, LaJolla, CA) and EGFr inhibition
(cetuximab) was assessed with and without radiation. Four human head and neck cell lines were studied: UM-SCC-1
and UM-SCC-5, and two modified UM-SCC-5 lines; a STAT-3 knockdown line (STAT-3-2.4) and control (NEG-4.17).
Exposure to either 0.5 μg/ml of cetuximab or 1 μM JAK1i for 8 or 24 h resulted in reduced activated STAT-3
(immunoblot), and the combination treatment showed greater reduction in activated STAT-3 compared to the
individual treatments. The use of either post-radiation JAK1i (1 μM for 72 h) or post-radiation cetuximab (0.5 μg/ml)
enhanced radiation-induced anti-proliferative and apoptotic effects but the greatest enhancement was seen when
cells were exposed to both JAK1i and cetuximab post-radiation. Similar results were seen for radiosensitization as
assessed by colony formation. Finally, the combination treatment of JAK1i (1 μM) and cetuximab (0.5 μg/ml), following
radiation, resulted in an increase of unrepaired radiation-induced DNA double strand breaks at 6 and 24 h after
radiation compared to the use of post-radiation JAK1i or cetuximab alone as delineated by neutral comet assay.
Conclusions: These findings suggest that dual inhibition of EGFr (cetuximab) and JAK-STAT-3 (JAK1i) leads to greater
radiosensitization than with either cetuximab or JAK1i alone and suggests that this combination treatment may be
clinically relevant even for tumors with a marked range of STAT-3 activity.
Background
Cetuximab is an inhibitor of the Epidermal Growth
Factor Receptor (EGFr) that binds to the EGFr ligand
binding domain, thereby inhibiting downstream EGFr
signaling involved in cellular growth [1]. In the clinic,
cetuximab has shown modest activity as a single agent
for metastatic head and neck cancer (13 % response rate
when used alone for recurrent disease) and radiosensitiz-
ing activity for locoregionally advanced head and neck
cancer [2–4]. Since the EGFr signaling pathway involves
multiple downstream phosphorylation reactions and
crosstalk with other signaling pathways, it is possible
that the anti-tumor effects of EGFr inhibition can be
enhanced by inhibiting other downstream effectors of
EGFr signaling.
The signal transducer and activator of transcription-3
(STAT-3) is a protein that lies downstream of EGFr and
activation of EGFr leads to activated STAT-3, which in
turn protects cells from apoptosis. However, it is also
known that several other signaling events activate
STAT-3. The Janus Kinases (JAK1 and JAK2) are im-
portant activators of STAT-3. Furthermore, other sig-
naling cascades, such as the SRC pathway, can activate
the JAK/STAT-3 cascade [5]. We have previously
shown that cetuximab-induced inhibition of EGFr leads
to inhibition of activated STAT-3, but this inhibition is
incomplete [1]. It is likely that other activators of
STAT-3, such as the Janus Kinases, circumvent more
complete STAT-3 inhibition when cetuximab is used
alone. Therefore, it is believed that STAT-3 continues
to affect downstream protection from apoptosis, and
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other STAT-3 mediated events such as angiogenesis,
even when it is partially inhibited by cetuximab.
In an effort to achieve more complete inhibition of
EGFr signaling, we explored the combined inhibition of
EGFr and JAK–STAT-3 (dual inhibition) with and with-
out radiation in human head and neck squamous cell
cancer cell lines with a variety of STAT-3 expression.
One of the tested cell lines had partial knockdown of
STAT-3 as previously described [6, 7]. It was determined
that JAK-STAT-3 inhibition accentuated the radiosensitiz-
ing properties of cetuximab in all cell lines. Although we
initially set out to determine whether JAK1i increased the
known cetuximab-induced radiosensitizing properties, we
found that both agents were radiosensitizers and the




Human head and squamous cell cancer cell lines were
grown in Dulbecco’s Modified Eagle’s Medium contain-
ing 10 % heat-inactive fetal bovine serum supplemented
with 2 μM L-glutamine and incubated in a humidified
chamber at 37 °C with 5 % CO2 as previously described
[6, 7]. UM-SCC-1 and UM-SCC-5 were obtained from
Dr. Thomas Carey at the University of Michigan. UM-
SCC-5 cells were used to create stable transfectants of a
short hairpin RNA against STAT-3 (STAT-3-2.4 cells).
These cells were created by transfecting UM-SCC-5 cells
with a pBABE-U6 vector containing STAT-3 short hair-
pin RNA (shRNA) as previously described [6]. Following
transfection, the STAT-3-2.4 cells showed approximately
50 % STAT-3 knockdown as previously described [6, 7].
Control cells were also previously created by transfection
with a mutated or negative STAT-3 shRNA form of the
short hairpin RNA against STAT-3 (NEG 4.17 cells) and
do not show significant STAT-3 knockdown [7].
Immunoblots
Immunoblots were used to analyze the protein expres-
sion levels of STAT3 as previously described [6, 7].
UM-SCC-1, −5 and transfected STAT3-2.4 and NEG4.17
cells were assessed for STAT-3, phosphorylated STAT-3
and GAPDH. Cell lysates were prepared and equal
amounts of protein were loaded in each gel lane. Separ-
ation was performed by 10 % sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS–PAGE) and
transferred to Immobilon-P membrane (Millipore Corp,
Bedford, MA). The immunoblots were blocked in 10 %
milk–Tris-buffered saline with Tween-20 (TBS-T)
(20 mmol/L Tris HCL [pH 7.5], NaCl 137 mmol/L, and
0.05 % Tween-20) for 1 h at room temperature. The
primary antibodies of anti-STAT-3, anti-p-STAT-3 (Cell
Signaling Technologies, Beverly, MA), anti-EGFr (Sigma-
Aldrich, St. Louis, MO), anti-p-EGFr (cell signaling
technologies, Beverly, MA) and anti-GAPDH (Santa
Cruz Technologies, Inc., Santa Cruz, CA) were incu-
bated overnight at 4 ° C with 2 % milk–TBS-T. The
secondary antibody, anti-mouse–IgG–horseradish per-
oxidase antibody (Sigma Chemical Company, St.
Louis, MO) was incubated at room temperature for
1 h. The blots were developed by chemiluminescence
(Amersham Life Sciences, Inc., Arlington Heights, IL).
Cell proliferation
The effects of various treatments on cell proliferation
were assessed by a cell proliferation assay as previously
described [6, 7]. Briefly, UM-SCC-1, −5, and the trans-
fected STAT3-2.4 and NEG 4.17 cells were plated in a
manner to allow multiple days of proliferation. Following
the entry of cells into an exponential growth phase, they
were exposed to various combinations of cetuximab
(0.5 μg/ml), 1 μM Janus Kinase inhibitor ([JAK1i] Calbio-
chem, LaJolla, CA) and/or radiation (2 Gy). The cells were
assessed for cell counts every 24 h. The cells were
removed from plates with trypsin and counted using a cell
counter (Beckman Coulter, Fullerton, CA). Illustrative
experiments demonstrate results following 72 h of growth.
Apoptosis
Apoptotic cell death following exposure to various
treatments was quantified by using the Annexin V-FITC
apoptosis detection kit (BioVision Research Products,
Mountain View, CA) as previously described [8]. UM-
SCC-1, −5, and the transfected STAT3-2.4 and NEG 4.17
cells were treated with various combinations of cetuximab
(0.5 μg/ml), JAK1i (1 μM) and/or radiation (2 Gy) in a
manner identical to the cell proliferation assay. Following
72 h of incubation, the cells were isolated and the data
were collected using a Becton Dickinson FACScan system.
This information was analyzed using CellQuest v3.1 soft-
ware (Becton Dickinson, San Jose, CA).
Colony formation
Cell survival was assessed by colony formation as previ-
ously described [6, 7]. Briefly, cells were plated the day be-
fore the start of the experiment in order to allow time for
attachment of the cells. The cells were exposed to various
doses of radiation, either alone or with exposure to JAK1i,
cetuximab or both agents just prior to radiation and dur-
ing the post-radiation period. The cells were allowed to
form colonies over 12–14 days. They were subsequently
fixed, stained and counted (colonies of > 50 cells) for col-
ony formation as previously described.
Neutral comet assay
The accumulation of DNA double strand breaks (dsbs)
was assessed by the neutral comet assay as previous
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described [7]. Briefly, exponentially growing UM-SCC-
1, −5, and the transfected UM-STAT3-2.4 and NEG
4.17 cells were plated at a concentration of 150,000
cells in 60 mm2 tissue culture dishes. After a 16 h
incubation in the presence of cetuximab (5 μg/ml),
JAK1i (1 μM) or the combined treatment with or with-
out radiation, the cells were scraped and processed for
Neutral Comet Assay at various times following radi-
ation as described by Trevigen (Gaithersberg, MD).
Following the staining with SYBR Green I, the slides
were viewed by fluorescence microscopy (Evos f1,
Advanced Microscopy Group, Bothell, WA). Tail
moment and percent DNA in the tail were analyzed
using CometScore Freeware.
Statistical analysis
All experiments were performed with at least three
independent experiments. Representative immunoblots
were selected for presentation. For experiments other
than the immunoblots, results were expressed as the
mean ± standard error (SE). For the cell proliferation
and apoptosis assays, the statistical significance between
treatment groups was determined using a two-way
ANOVA assessment with software from GraphPad
Prism, San Diego, California. Overall comparisons of
certain conditions were made using comparisons of
all four cell lines in a simultaneous two-way ANOVA
assessment.
Ethics
This research did not involve human subject.
Results
Since cetuximab and JAK1i have previously been shown
to have anti-proliferative properties [1, 9, 10], studies were
performed to determine the concentration-response
characteristics of these agents with respect to their
anti-proliferative effects in human head and neck
squamous cell carcinoma cell lines. Utilizing the UM-
SCC-1 cells, we sought to find concentrations of
these agents that resulted in less than 60 % reduc-
tions in proliferation after 72 h exposures. This min-
imal effective level was sought because subsequent
experiments would involve combinations of the agents
and it was felt that more effective exposures could
blunt the meaningful examination of combining these
agents. When UM-SCC-1 cells were treated with
5 μg/ml (or less) of cetuximab alone or 1 μM (or
less) of JAK1i alone for 72 h, the resulting anti-
proliferative effects were less than 60 % inhibition
(Fig. 1). Similar results were found in the other stud-
ied cell lines. Therefore, these concentration ranges
(for the two agents) were utilized for subsequent
experiments. It is noteworthy that the subsequently
studied combination effects varied somewhat with the
concentrations of JAK1i or cetuximab (Figs. 3 and 4).
Next, the assessment of EGFr inhibition (cetuximab),
with or without the addition of JAK-STAT-3 inhibition
(JAK1i), and its effect on STAT-3 protein expression in
four human head and neck cancer cell lines was studied.
The STAT-3 knockdown cells (STAT 3–2.4) previously
demonstrated approximately 45–55 % less STAT-3
protein compared to the control cells (NEG 4.17) [6, 7].
Immunoblots were used to assess the effects of vari-
ous treatments on overall STAT-3, activated STAT-3
(primarily p-STAT-3 [Tyr 705] and to a lesser extent
p-STAT-3 [Ser 727]). The immunoblots were performed
with and without 5 mins of EGF stimulation at the end of
each treatment (Fig. 2). For the UM-SCC-1 cells, STAT-3
protein was assessed at 8 and 24 h following exposure to
cetuximab alone (0.5 μg/ml), JAK1i (1 μM) alone or cetux-
imab and JAK1i. The remaining cell lines were assessed
after 24 h exposures to the agents (Fig. 2c). The UM-SCC-
1 cells showed a suggestion of a decrement in overall
STAT-3 with the combination treatment (JAK1i and
cetuximab) at 8 and 24 h (Fig. 2a and b), but the other cell
lines did not show consistent reductions in overall STAT-
3 with these treatments (Fig. 2c). However, activated
STAT-3 was decreased with either cetuximab or JAK1i
and the greatest decrement in activated STAT-3 was
generally seen for the combination of cetuximab and
JAK1i. Figure 2c also demonstrates the decreased STAT-3
levels in the STAT-3 knockdown cells (STAT 3–2.4) com-
pared to control (NEG 4.17) or parental a (UM-SCC-5)
cells. The latter three cell lines were also assessed for
EGFr and p-EGFr (Tyr 1086) following the same 24 h
exposures (noted above for p-STAT-3 assessments) to the
two inhibitors (Fig. 3). Cetuximab, with or without JAK1i
resulted in decreased p-EGFr but JAK1i alone caused an
increase in p-EGFr possibly due to a feedback mechanism.
Since the immunoblot results demonstrated enhanced
inhibition of p-STAT-3 for the combination of JAK1i
and cetuximab, studies were performed to determine if
the combination of the two agents resulted in a greater
impact on radiation-induced anti-proliferation or apop-
totic effects compared to treatments with the individual
agents. These studies were building on previous studies
in which STAT-3 knockdown was found to accentuate
the effects of radiation [6]. The UM-SCC-1 cells were
assessed for proliferation changes and apoptosis follow-
ing exposure to JAK1i alone (0.5 μM), cetuximab alone
(0.5 μg/ml), the combination of the two inhibitors, each
inhibitor with radiation (2 Gy) or the combination of
inhibitors with radiation (Fig. 4). Each individual
inhibitor accentuated the anti-proliferative effects of
radiation in UM-SCC-1 cells (Fig. 4). Furthermore,
when JAK1i was added to the combination treatment
of cetuximab and radiation, there was an enhancement
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of the anti-proliferative effects compared to cetuximab
and radiation without JAK1i. Also, there was a signifi-
cantly greater effect regarding the inhibition of prolif-
eration when radiation was combined with the two
inhibitors compared to the two inhibitors without
radiation. These findings were mirrored by studies
examining apoptosis for the UM-SCC-1 cells (Fig. 4).
The addition of JAK1i to cetuximab and radiation
resulted in greater apoptosis, that was statistically
significant, compared to cetuximab and radiation
without JAK1i (Fig. 4). Additionally, apoptosis was
significantly greater for the two inhibitors in combin-
ation with radiation compared with the two inhibitors
without radiation (Fig. 4). Therefore, the dual inhibition of
STAT-3 and EGFr showed greater anti-proliferative effects
and apoptosis compared to the use of either single
inhibitor and dual inhibition accentuated radiation-
induced anti-proliferative effects and apoptosis to a
greater extent compared to either single inhibitor in
the UM-SCC-1 cells.
Next, additional cell lines were studied to test whether
these results were potentially generalizable. Cell lines
with various levels of STAT-3 were assessed. Cell prolif-
eration assessments were undertaken for all four cell
lines under similar conditions (slightly different JAK1i
concentration) as noted above for the UM-SCC-1 cells.
Greater decrements in cell proliferation were noted
following exposure to both agents (JAK1i, [1 μM] and
cetuximab [0.5 μg/ml] for 72 h), compared to either
agent alone in these additional cell lines (Fig. 5). The
various cell lines showed slightly different sensitivities to
cetuximab alone or JAK1i alone. Compared to the pre-
vious experiments with UM-SCC-1 (Fig. 4), these studies
were undertaken with a slightly higher concentration of
JAK1i (1 μM) that interacted substantially with both
cetuximab and radiation. The overall significance (taking
into account all four cell lines) of adding JAK1i to cetux-
imab and RT [p = 0.0001] was pronounced. Likewise,
there was a significant effect for the addition of cetuxi-
mab to JAK1i and RT [p = 0.0001]. However, when the
higher concentrations of JAK1i (1 μM) were utilized
(compared to early experiments [Fig. 4]), there was a
more pronounced interaction between JAK1i and cetuxi-
mab. Therefore, there was only a suggestion that the
overall inhibition of proliferation for radiation with the
two inhibitors was greater compared to the two inhibi-
tors without radiation. Additionally, when the four cell
lines were assessed individually, the use of combined
cetuximab/JAK1i resulted in significantly enhanced
radiation-induced anti-proliferation compared to the use
of either agent alone (Fig. 5). Although these effects of
treatment with cetuximab, JAK1i and radiation were con-
sistent with the immunoblot data in Fig. 2, some cell lines
showed greater inhibitory effects with immunoblot data
which did not directly correlate with greater effects re-
garding the anti-proliferative effects. These findings sug-
gested that EGFr and STAT-3 were just two of many
factors affecting radiosensitivity.
Since STAT-3 is known to protect cells from apop-
tosis, the above noted treatment-related effects on cell
Fig. 1 Concentration-response assessments were made for JAK1i and cetuximab in UM-SCC-1 cells as a representative cell line. Cells were exposed to
various concentrations of the inhibitors for 72 h and subsequently assessed for proliferation as described in the methods section
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proliferation were further assessed to determine if they
correlated with apoptotic events. Cetuximab and/or JAK1i
were tested with and without radiation (Fig. 5). The results
correlated with the cell proliferation findings. As with the
cell proliferation studies, greater apoptosis was seen when
JAK1i was added to the combination of cetuximab and
radiation. The overall levels of significance for the com-
parisons of cetuximab/JAK1i with RT vs. either cetuximab
Fig. 2 Immunoblot analyses revealed that the phosphophorylation of STAT-3 was significantly reduced with the dual treatment of cetuximab and
JAK1i as compared to either individual agent alone. UM-SCC-1, UM-SCC-5, STAT-3 knockdown cells (STAT3-2.4) and control transfected cells (NEG4.17) were
treated with cetuximab (5 μg/ml) and/or JAK1i (1 μM) for either 8 or 24 h with or without 5 mins of exposure to EGF (60 ng/ml) and subsequently assessed
as described in the methods section. Protein lysates were subjected to SDS-PAGE and Western blot analysis for STAT-3, p-STAT-3(Tyr705)
and p-STAT-3(Ser727). GAPDH was used to control for loading variability. Representative immunoblots for the UM-SCC-1 cells assessed at
8 h a and 24 h b are shown. Representative immunoblots for the remaining cell lines are shown for the 24 h time point c
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with RT [p = 0.0001], or JAK1i with RT [p = 0.0001], were
pronounced. These effects were statistically significant for
all individual cell lines except the comparison of cetuxi-
mab/JAK1i with RT vs. cetuximab and RT in the control
transfectants (NEG 4.17 cells). As with the proliferation
studies, there was a suggestion that cetuximab/JAK1i and
RT produced more apoptosis than cetuximab/JAK1i, but it
was not significant [p > 0.05]. Once again, this comparison
was significant when cells were exposed to lower concen-
trations of JAK1i (0.5 μM) as shown in Fig. 4. In summary,
these findings correlated with the cell proliferation studies
and demonstrated increased enhancement of radiation-
induced apoptosis with the combination of cetuximab/
JAK1i compared to the use of either agent alone.
Following the studies of cellular proliferation and apop-
tosis, it was important to assess cell survival. A standard
colony formation assay was used for these studies. A
representative experiment for UM-SCC-1 cells is shown
(Fig. 6). UM-SCC-1 cells were exposed to either JAK1i
alone (1 μM), cetuximab (0.5 μg/ml) alone or the com-
bination of JAK1i and cetuximab just prior to radiation.
The combination of JAK1i and cetuximab resulted in
marked radiosensitization whereas exposure to either
agent alone did not result in radiosensitization under
these conditions (Fig. 6).
Since the cytotoxic effects of radiation are associated
with the induction of DNA double strand breaks (dsbs),
studies were performed to determine whether the
addition of JAK1i to cetuximab and radiation resulted in
Fig. 4 The addition of JAK1i (0.5 μM) to cetuximab and radiation resulted in an enhancement of radiation-induced anti-proliferative (left) and apoptosis
effects (right) in UM-SCC-1 cells. Cells were treated for 72 h with cetuximab (0.5 μM) with and without radiation (2 Gy) and subsequently assessed for
cell proliferation or apoptosis as described in the methods section
Fig. 3 Immunoblot analyses revealed that cells treated with
cetuximab (5 μg/ml) and the combination of cetuximab and JAK1i
(1 μM) showed reductions in p-EGFr. Additionally, cells treated with
JAK1i (1 μM) alone showed increased p-EGFr. Parental UM-SCC-5
cells, STAT-3 knockdown cells (STAT3-2.4) and control transfected
cells (NEG 4.17) were treated with cetuximab (5 μg/ml) and/or JAK1i
(1 μM) for 24 h (with and without 5 mins of exposure to EGF
[60 mg/ml] at the end of the 24 h) and assessed for p-EGFr, EGFr
and GAPDH as described in the methods section
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Fig. 5 The use of JAK1i (1 μM) increased the effects of cetuximab (0.5 μg/ml) in all four cell lines when cell proliferation or apoptosis
was assessed. The data represent the mean and standard error of three assessments. Top. Cell proliferation was assessed 72 h after
indicated treatments and normalized to vehicle-treated cells (100 %). Bottom. Apoptosis was assessed in exponentially growing cells that
were collected after 72 h treatments and analyzed using Annexin V-FICT kit
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greater induction of DNA dsbs as assessed by the neu-
tral comet assay. A representative example of these
studies for the UM-SCC-1 cells is shown in Fig. 7.
UM-SCC-1 cells were exposed to cetuximab (0.5 μg/
ml) for one hour prior to radiation with and without
JAK1i (1 μM) for 5 mins prior to radiation. The induc-
tion of DNA dsbs was similar for radiation alone, radi-
ation with either JAK1i or cetuximab and radiation
with both JAK1i and cetuximab (Fig. 7). Therefore, the
addition of one or both of the two inhibitors did not
affect the induction of DNA dsbs.
Since cetuximab-induced radiosensitization is asso-
ciated with the inhibition of DNA dsb repair [8, 11],
studies were performed to determine if the addition
of JAK1i to cetuximab and radiation accentuated this
effect. The assessment of DNA dsb repair by the
neutral comet assay revealed that the addition of
JAK1i to cetuximab resulted in more pronounced
inhibition of the repair of DNA damage compared to
cetuximab alone in all four cell lines (Fig. 8). Furthermore,
the combination of cetuximab and JAK1i resulted in more
pronounced inhibition of radiation-induced DNA dsb
repair compared to cetuximab-mediated or JAK1i-
mediated inhibition of radiation-induced DNA repair
(Fig. 8). This effect was demonstrated at 6 and 24 h
of repair time in all four cell lines. Taken together,
these results suggest that DNA repair is potentially
mechanistically involved in the increase in radiosen-
sitization when JAK1i is added to cetuximab and
radiation.
Discussion
Human head and neck squamous cell carcinoma cancer
cells show high levels of EGFr expression and it is
believed that this expression plays an important role in
the EGFr-mediated receptor tyrosine kinase signaling
that controls cellular proliferation and can lead to the
aggressive growth of these tumors [1]. Increased expres-
sion of EGFr has correlated with a poor prognosis for
patients with head and neck cancer treated with conven-
tional therapies [12]. The significance of EGFr in the
growth of head and neck malignancies led many investi-
gators to explore the use of anti-EGFr treatments in this
disease. These efforts proved fruitful as anti-EGFr treat-
ments have been effective as single agent therapies or in
combination with chemotherapy for patients with meta-
static disease [2, 4]. Additionally, the inhibition of EGFr
has resulted in clinically significant radiosensitization for
locoregionally advanced tumors [3].
Even though anti-EGFr treatments, such as cetuximab
are effective in head and neck cancer, it is known that
the EGFr pathway receives additional signaling input
from other parallel growth pathways [13]. It is believed
that these parallel growth pathways can partially circum-
vent the anti-proliferative effects of anti-EGFr agents,
such as cetuximab, by activating proteins that are down-
stream of EGFr. Therefore, we sought to enhance the
anti-proliferative and radiosensitizing effects of cetuxi-
mab by adding an inhibitor of STAT-3 which is an
important downstream tyrosine kinase that facilitates
protection from apoptosis. Others have targeted STAT-3
Fig. 6 The use of JAK1i (1 μM) combined with cetuximab (0.5 μg/ml) prior to radiation resulted in marked radiosensitization in UM-SCC-1 cells.
JAK1i alone or cetuximab alone did not result in radiosensitization. The data represent the mean and standard error of three assessments
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Fig. 7 The addition of cetuximab, JAK1i or the combination of cetuixmab and JAK1i prior to radiation did not enhance the number of
radiation-induced DNA double strand breaks. UM-SCC-1 cells were treated with cetuximab (0.5 μg/ml) for one hour with and without
JAK1i (1 μM) added 5 mins prior to radiation (2 Gy) and subsequently assessed for the mean tail moment as measured by the neutral
comet assay and described in the methods section
Fig. 8 The addition of JAK1i (1 μM) resulted in less repair of radiation-induced DNA dsbs at 6 and 24 h following radiation (2 Gy) compared to
cetuximab (0.5 μg/ml) and radiation without JAK1i as measured by the neutral comet assay in all four cell lines. Top. The mean tail moment for
6 h of treatments alone or proceeded by radiation. Bottom. The mean tail moment for 24 h. Following treatment, exponentially growing cells
were collected and processed for single-cell gel electrophoresis assay (Trevigen’s Comet Assay)
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in human tumor models using various techniques.
Grandis, et al., stably transfected human head and neck
cancer cells with dominant negative mutant STAT-3
constructs. This alteration resulted in these constructs
failing to proliferate [14]. In contrast, a similar dominant
negative construct for STAT-1 did not alter the prolifer-
ation of the cells.
Recently, this same group, Sen et al. [15], further
assessed the effect of targeting STAT-3, utilizing decoy
nucleotide sequences that interfere with STAT-3 mediated
DNA binding, on the growth rate of cetuximab-sensitive
parental T24 squamous cell cancer cells and T24 cells
with acquired resistance to cetuximab. The targeting of
STAT-3 decreased proliferation in both the cetuximab
sensitive and cetuximab resistant cells. These cells were
then grown as xenografts and the combination of
cetuximab and STAT-3 decoy was assessed. Treatment of
either cetuximab-sensitive or cetuximab-resistant cells
with cetuximab and STAT-3 decoy resulted in significant
reductions in tumor volume compared to cetuximab with
a control mutant decoy. They also showed that STAT-3
levels were increased in squamous cell tumors (patient
samples) that recurred following cetuximab treatment.
Due to the above findings, they hypothesized that the
application of STAT-3 inhibitors may be useful in circum-
venting cetuximab resistance. They did not examine the
use of radiation or cetuximab-induced radiosensitization
in these experiments.
The work of Sen et al., may serve as appropriate
preliminary preclinical data to consider combining
inhibitors of EGFr and STAT-3 for incurable tumors
[15]. However, adding JAK1i to the combination of
cetuximab and radiation could potentially enhance the
cure rate of cetuximab and radiation for patients with
locoregionally advanced disease. In fact, cetuximab is a
known radiosensitizer and only partially inhibits the acti-
vation of STAT-3 and hence, we employed a combination
of cetuximab and a JAK1-STAT-3 inhibitor (JAK1i) with
or without radiation. This approach showed that the two
agents interacted to enhance the inhibition of cellular
proliferation and promote apoptosis compared to either
agent alone. These results corroborated the results of Sen
et al. [15]. Furthermore, the addition of JAK1i enhanced
the radiosensitizing effects of cetuximab in human head
and neck cancer cells. Finally, our results showed that the
combination of the two agents inhibited radiation-induced
DNA repair to a greater extent than either agent alone.
These effects were demonstrated in four human head and
neck squamous cell cancer cell lines including STAT-3-2.4
cells which showed 50 % STAT-3 knockdown as a result
of stable transfection of a short hairpin RNA against
STAT-3. This latter result increases the potential ramifica-
tions of this study. It is very possible that this dual
approach to the inhibition of EGFr signaling (that includes
anti-STAT-3) may be clinically relevant for tumors with
low to high levels of STAT-3 activation.
The findings that the addition of JAK1i to cetuximab
and radiation enhanced the anti-proliferative, apoptotic
and radiosensitizing effects of radiation and the accom-
panying result that there was no appreciable difference
in this effect for STAT-3 knockdown cells vs. parental
cells, may not have been expected. One might have
expected JAK1i to be less of a radiosensitizer or add less
to the cetuximab-radiation interaction in the STAT-3
knockdown cells. However, this was not the case. These
results suggest that even though STAT-3 expression may
be reduced in a particular cell line, STAT-3 remains a
significant partner with EGFr (and other receptors)
regarding the sensitivity of the cell to radiation. It will
also be important to investigate whether STAT-3 is a
more important driver of EGFr signaling in cell lines
with certain molecular characteristics. This information
could help investigators exploit STAT-3 inhibition as a
clinical target for personalized medicine approaches.
Our study did not provide information in this regard.
The STAT-3 knockdown cells and parental cells showed
similar effects for the studied conditions.
The aforementioned studies were performed based on
previous work that demonstrated cetuximab radiosensi-
tized human head and neck squamous cell cancers [1].
The previous findings that cetuximab was a radiosensiti-
zer for squamous cell carcinomas initiated many add-
itional laboratory and clinical investigations in the early
2000’s. Our group reported that cetuximab enhanced
radiation-induced apoptosis in human squamous cell
cancer, but we did not explore the induction or repair of
radiation-induced DNA damage in those early studies.
However, following the demonstration that cetuximab
was clinically useful as a radiosensitizer [3], others re-
ported that cetuximab inhibited radiation-induced DNA
dsb repair [11]. Although cetuximab alters many signaling
pathways that could affect radiosensitivity, the potential
role of DNA repair in cetuximab-induced radiosensiti-
zation for certain cell populations led to the DNA
repair studies reported herein. The findings that the
addition of JAK1i to cetuximab and radiation resulted
in greater radiosensitization and greater slowing of the
repair of radiation-induced DNA dsbs are intriguing.
Cetuximab’s known effect of slowing the repair of
radiation-induced DNA dsbs is hypothesized to be in-
volved in at least a portion of cetuximab-induced radio-
sensitization in many cell lines. Cetuximab also
influences cellular processes such as cell cycle, apop-
tosis, and angiogenesis. It is likely that these effects play
a role in cetuximab-induced radiosensitization as well
[16, 17]. As with cetuximab, it is entirely possible that
JAK1i creates many effects (due to altered signaling of
several pathways) that are involved in radiosensitivity, but
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our results suggest that greater slowing of the repair
of radiation-induced DNA dsbs contributes to the
JAK1i - mediated enhancement of cetuximab-induced
radiosensitization.
Others have explored the dual inhibition of molecular
targets as a method of enhancing the effects of radiation
in head and neck cancer by targeting various aspects of
EGFr signaling. It is known that EGFr signaling pro-
motes angiogenesis [18]. Cetuximab leads to a partial
decrease in angiogenesis for human head and neck
cancer [18]. (This partial cetuximab-induced inhibition
is similar to cetuximab’s effect on STAT-3). It is believed
that cetuximab-mediated inhibition of EGFr leads to
partial reduction in angiogenesis through downregulation
of HIF-1a and Notch 1 [18]. Since preclinical studies have
shown that cetuximab partially inhibits angiogenesis and
this inhibition appears to hinder tumor growth, investiga-
tors have been interested in combining cetuximab with
anti-VEGF agents, such as, bevacizumab. Additionally,
there has been interest in combining both agents with
radiation in head and neck cancer. Recently, the Memorial
Sloan Kettering group treated 30 patients with locoregion-
ally advanced head and neck cancer with cetuximab
(400 mg/m2 loading dose, followed by 250 mg/ml weekly),
bevacizumab (15 mg/kg, day 1 and 22) and cisplatin
(50 mg/m2, day 1, 2, 22 and 23) concomitantly with radio-
therapy (70 Gy). The early results have been promising
with an overall survival of 92.8 % at 2 years [19]. Further
work will be necessary to determine if the use of this
particular combination of dual inhibitors of molecular
targets, for the purpose of enhancing radiosensitization, is
an advance in the clinical arena.
Additional investigations have employed dual radio-
sensitizers in head and neck cancer by combining
cisplatin with targeted agents. (It is noteworthy that
reduced cisplatin doses were employed in the above
noted clinical trial with cetuximab, bevacizumab and
radiation). Cisplatin has long been used as a radiosen-
sitizer in head and neck cancers. After cetuximab was
found to be a radiosensitizer for head and neck can-
cer, interest arose in combining cisplatin and cetuxi-
mab as dual radiosensitizers. The Radiation Therapy
Oncology Group (RTOG) recently reported the results
of a large phase III study that explored the use of
cisplatin-radiotherapy with and without cetuximab for
patients with locoregionally advanced head and neck
cancer. Unfortunately, the addition of cetuximab to
the combination of cisplatin and radiotherapy did not
result in a benefit for patients [20]. In the future,
combinations of targeted agents with radiotherapy
could prove to be an area of impactful investigation
as there may be complementary targeted agents that
enhance tumor kill without significantly increasing
toxicity.
Conclusion
Our work and the work of others suggest that combina-
tions of agents that target overlapping signal transduc-
tion pathways may be a means to address relative
resistance to single agents [21]. The present study sug-
gests that the combination of inhibitors of EGFr and
STAT-3 enhances the effects of radiation in head and
neck cancer compared to the use of either agent alone.
Inhibitors of STAT-3 are being investigated [22] and
these agents could be combined with cetuximab in fu-
ture clinical trials.
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